

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Votrient (pazopanib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Votrient (pazopanib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Votrient (pazopanib) may be approved if the following criteria are met:

Individual has a diagnosis of one of the following:

- I. Advanced renal cell carcinoma (kidney cancer);

OR

- II. Soft tissue sarcoma (STS) (label, NCCN 2A);

AND

- A. Votrient (pazopanib) is being used as palliative therapy for cancers of the extremity/superficial trunk, head/neck or retroperitoneal/Intra-abdominal; **OR**
- B. Votrient (pazopanib) is being used as palliative therapy for angiosarcoma or rhabdomyosarcoma; **OR**
- C. For disease progression of Gastrointestinal Stromal Tumors after single-agent therapy with imatinib, sunitinib, and regorafenib;

OR

- III. Uterine sarcoma (NCCN 2A);

OR

- IV. Thyroid carcinomas (NCCN 2A);
 - A. For Follicular, Papillary, or Hurthle Cell thyroid carcinomas if clinical trials or other systemic therapies are not available or appropriate for treatment of progressive and/or symptomatic iodine-refractory disease; **OR**
 - B. For Medullary carcinomas in the treatment of progressive disease or symptomatic distant metastases if clinical trials, cabozantinib, or vandetanib are not available or appropriate, **OR** if there is progression on vandetanib or

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

cabozantinib;

OR

V. Ovarian cancer (NCCN 2A).

Votrient (pazopanib) may **not** be approved for the following:

I. For the treatment of adipocytic STS (NCCN 2A).

Note: Votrient (pazopanib) has a black box warning for hepatotoxicity. Severe and fatal hepatotoxicity has occurred in clinical trials. Hepatic function should be monitored and therapy interrupted, reduced, or discontinued as recommended.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: 4/2018.

DrugPoints® System [Internet Database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.